Peptide Vendor Enforcement Timeline 2024-2026: Letters, Raids, Pleas, Sentences | Artemis Labs
Peptide Vendor Enforcement Timeline 2024-2026
Published August 21, 2026 · Artemis Labs
Peptide vendor enforcement timeline 2024-2026 — The peptide vendor enforcement timeline 2024-2026 runs from four FDA warning letters dated December 10, 2024, through the June 2025 Amino Asylum raid and the December 10, 2025 Paradigm Peptides guilty pleas, to the March 2026 Peptide Sciences shutdown, the seven-letter FDA batch, and sentencing on July 30, 2026.
Key findings
- The sequence escalated in kind, not just in count. Warning letters in 2024, a physical facility raid in 2025, guilty pleas at the end of 2025, a mass letter batch and a voluntary shutdown in early 2026, and prison sentences by mid-2026.
- The chronology holds two kinds of dates. Paradigm Peptides’ website went offline in March 2024 — well before the December 2025 pleas. A vendor’s disappearance and its legal resolution are separate events with separate dates.
- Demand did not fall with supply. Industry keyword estimates put US peptide search demand up 398% year over year, at roughly 10.1 million monthly US searches, while the vendor list contracted.
The timeline, dated
| Date | Event | Record |
|---|---|---|
| March 2024 | Paradigm Peptides’ website goes offline — before any public charges in the case. | Case chronology via CBS News |
| December 10, 2024 | FDA issues four warning letters to research-peptide sellers: Summit Research Peptides (695607-12102024), Prime Vitality Inc dba Prime Peptides (695156-12102024), Xcel Research LLC (694608-12102024), and SwissChems (same batch). | FDA warning-letter index |
| ~June 18, 2025 | FDA agents raid Amino Asylum’s warehouse facility — the first physical raid on a major vendor. The site goes dark overnight; payment processing ends; pending orders are frozen. Traffic-estimate services placed the site near 400,000 monthly visitors at the time. | Contemporaneous industry reporting |
| December 10, 2025 | Matthew Kawa (48, owner of Paradigm Peptides) pleads guilty to introducing unapproved drugs into interstate commerce with intent to defraud and mislead, and to illegally importing merchandise. Jennifer Stechkober (32) also pleads guilty. | U.S. Attorney’s Office, N.D. Indiana; CBS News |
| March 6, 2026 | Peptide Sciences announces a voluntary shutdown and halts all order processing; the closure notice states that any further sales under its brand are fraudulent. The site goes offline shortly after. | Company closure notice |
| March 31, 2026 (posted April 7) | FDA issues seven warning letters in one batch to research-peptide sellers in six states. | FDA warning-letter index |
| July 30, 2026 | Sentencing in South Bend (N.D. Indiana): Kawa receives 70 months, one year of supervised release, and $5 million in forfeiture; Stechkober receives 16 months. | CBS News; court record |
From letters to sentencing: the escalation pattern
Each stage of the peptide vendor enforcement timeline used a heavier instrument than the last. The December 2024 letters were administrative: public notices with a 15-working-day response window. The June 2025 Amino Asylum raid was physical: agents at a warehouse, a site dark by morning. The December 2025 Paradigm Peptides pleas were criminal: individual owners admitting federal charges. And July 2026 converted those pleas into prison terms and a $5 million forfeiture. The seven-letter batch of March 31, 2026 — analyzed letter by letter in our FDA peptide warning letters April 2026 reference — shows the administrative track scaling up in parallel with the criminal one, seven sites in a single day against December 2024’s four.
What the Paradigm Peptides case established
The Paradigm Peptides case is the timeline’s only completed criminal arc, and its details reward attention. Per the court record, the products included peptides, hCG, and SARMs — and products labeled as SARMs contained testosterone, a Schedule III substance. The charge Kawa admitted was selling unapproved drugs with intent to defraud and mislead — the intent element is part of the plea itself. The case is, among other things, a documented instance of label-versus-contents divergence — the exact failure that third-party identity testing exists to catch, as our Certificate of Analysis guide details.
One postscript: after the original site went offline, a similarly named site (paradigmpeptides.is) appeared and itself stated it had no affiliation with the original company. Lookalike domains trailing a dead vendor’s brand are now a recurring feature of these closures.
Why the chronology has two kinds of dates
A vendor’s storefront going dark and a vendor’s legal record being resolved are different events, sometimes years apart. Paradigm Peptides’ site went down in March 2024; the guilty pleas came in December 2025, and sentencing in July 2026. Peptide Sciences inverted the pattern — no public enforcement action against it appears in this record; the company closed voluntarily on March 6, 2026, and its own closure notice declared any further sales under its brand fraudulent, which is why sites reusing that brand since should be read as unaffiliated.
The distinction also guards against a documented confusion: published summaries have conflated Amino Asylum and Paradigm Peptides, attaching the same individuals to both. The record separates them cleanly — the Kawa and Stechkober pleas belong to the Paradigm Peptides case; Amino Asylum’s event in this timeline is the June 2025 raid, and its founders’ legal outcomes are not established in the sources this page relies on.
Market context: demand rose while the vendor list shrank
The enforcement wave landed on a growing market, not a shrinking one. Industry keyword estimates put peptide-related US search demand up 398% year over year, at roughly 10.1 million monthly searches, with single compounds such as BPC-157 near 165,000 monthly queries. Compliance-tracking tallies count more than 100 FDA warning letters to peptide and research-chemical sellers since September 2025. All figures are third-party estimates and should be attributed as such — but the direction is consistent: more researchers looking, fewer vendors standing, and the surviving vendors publishing successor guidance at volume.
For researchers navigating that gap, the working documents are the hub on peptide vendor closures 2025-2026 and the supplier evaluation framework. Artemis Labs publishes this chronology as reference material for laboratory researchers — its own catalog and the literature behind it are documented in the research library, for research use only.
FAQ
When did Paradigm Peptides shut down?
Its website went offline in March 2024 — before any public charges. The guilty pleas of Matthew Kawa and Jennifer Stechkober came December 10, 2025, and sentencing followed on July 30, 2026: 70 months plus $5 million in forfeiture for Kawa, 16 months for Stechkober.
What happened to Peptide Sciences?
Peptide Sciences announced a voluntary shutdown on March 6, 2026, halted all order processing, and went offline shortly after. Its closure notice stated that any further sales under its brand are fraudulent; no public enforcement action against the company appears in this timeline’s record.
Was Amino Asylum part of the Paradigm Peptides case?
No. The two are separate: Amino Asylum’s warehouse was raided by FDA agents around June 18, 2025, while the Kawa and Stechkober pleas belong entirely to the Paradigm Peptides case. Some published summaries have merged the two — the primary records do not.
How many FDA warning letters have gone to peptide sellers?
More than 100 since September 2025, per compliance-tracking tallies — an estimate, not an official FDA statistic. The dated anchors in this timeline are the four-letter batch of December 10, 2024, and the seven-letter batch dated March 31, 2026.
References
- FDA Warning Letter, Summit Research Peptides, 695607-12102024. fda.gov
- FDA Warning Letter, Prime Vitality Inc dba Prime Peptides, 695156-12102024. fda.gov
- FDA Warning Letter, Xcel Research LLC, 694608-12102024. fda.gov
- FDA Warning Letters index (SwissChems, December 2024; Prime Sciences, PekCura Labs, FormPour, Guangzhou Huli Technology dba Fantasy Face, March 2026). fda.gov
- FDA Warning Letter, Lovega LLC dba Pink Pony Peptides, 721088-03312026. fda.gov
- CBS News, sentencing report in the Paradigm Peptides case. cbsnews.com
- Policy Canary, “FDA research-peptide warning letters, April 2026.” policycanary.io
- The Partnership for Safe Medicines, batch summary PDF (posted April 7, 2026). safemedicines.org
